This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Potassium Rollercoaster Heartbreak
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Trial by Combat: Do Amino Acids provide PROTECTION to the Kidneys?
FLOW - El Resumen Visual
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
FLOW- the Visual Abstract
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
FLOWing with the SemagluTIDE
Healing, Hype, or Harm: The NefIgArd trial
The PROTECT-V platform - RENALISM no more?
Dialysis dreams and sleepless realities: the SLEEP-HD trial
The SLEEP-HD Visual Abstract
Check out the dreamy Visual Abstract by Cristina Popa
Any sleep potion for insomnia in patients on hemodialysis?
🤔 E-alerts in AKI, the ELAIA-2 trial
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes (Wilson, Nature Communications 2023)
🤔 RCT comparing Cefepime with Pip/Taz and AKI
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial (Quian, JAMA 2023)
🤔 Sparsentan in IgA Nephropathy
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Rovin, Lancet 2023)
